129 related articles for article (PubMed ID: 22749703)
1. Patient satisfaction following Bio-Alcamid injection for facial contour defects.
George DA; Erel E; Waters R
J Plast Reconstr Aesthet Surg; 2012 Dec; 65(12):1622-6. PubMed ID: 22749703
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
[TBL] [Abstract][Full Text] [Related]
3. Experience with Bio-Alcamid, a new soft tissue endoprosthesis.
Lahiri A; Waters R
J Plast Reconstr Aesthet Surg; 2007; 60(6):663-7. PubMed ID: 17485056
[TBL] [Abstract][Full Text] [Related]
4. Complications after treatment with polyalkylimide.
Schelke LW; van den Elzen HJ; Canninga M; Neumann MH
Dermatol Surg; 2009 Oct; 35 Suppl 2():1625-8. PubMed ID: 19807756
[TBL] [Abstract][Full Text] [Related]
5. Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy.
Nadarajah JT; Collins M; Raboud J; Su D; Rao K; Loutfy MR; Walmsley S
Clin Infect Dis; 2012 Dec; 55(11):1568-74. PubMed ID: 22942210
[TBL] [Abstract][Full Text] [Related]
6. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
[TBL] [Abstract][Full Text] [Related]
7. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Ramon Y; Fodor L; Ullmann Y
Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
[TBL] [Abstract][Full Text] [Related]
8. The polyalkylimide gel: experience with Bio-Alcamid.
Claoue BL; Rabineau P
Semin Cutan Med Surg; 2004 Dec; 23(4):236-40. PubMed ID: 15745232
[TBL] [Abstract][Full Text] [Related]
9. Early and late complications of polyalkylimide gel (Bio-Alcamid)®.
Nelson L; Stewart KJ
J Plast Reconstr Aesthet Surg; 2011 Mar; 64(3):401-4. PubMed ID: 20637713
[TBL] [Abstract][Full Text] [Related]
10. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients.
Hönig J
J Craniofac Surg; 2008 Jul; 19(4):1085-8. PubMed ID: 18650737
[TBL] [Abstract][Full Text] [Related]
11. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
12. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
Silvers SL; Eviatar JA; Echavez MI; Pappas AL
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):34S-45S. PubMed ID: 16936543
[TBL] [Abstract][Full Text] [Related]
13. Late-onset gluteal Escherichia coli abscess formation 7 years after soft tissue augmentation with Bio-Alcamid in a HIV-positive patient.
Campana M; Lazzeri D; Rosato L; Perello R; Vaccaro M; Ciappi S; Campa A; Brafa A; Nisi G; Brandi C; Grimaldi L; D'Aniello C
J Plast Reconstr Aesthet Surg; 2010 Sep; 63(9):e709-10. PubMed ID: 20462820
[No Abstract] [Full Text] [Related]
14. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: a prospective multicenter study for evaluation of safety and aesthetic results in 101 patients.
von Buelow S; Pallua N
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):85S-91S. PubMed ID: 16936548
[TBL] [Abstract][Full Text] [Related]
16. Complications after treatment with polyalkylimide.
Schelke L
Dermatol Surg; 2011 Jan; 37(1):125. PubMed ID: 21070467
[No Abstract] [Full Text] [Related]
17. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
[TBL] [Abstract][Full Text] [Related]
18. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.
Negredo E; Puig J; Aldea D; Medina M; Estany C; Pérez-Alvarez N; Rodríguez-Fumaz C; Muñoz-Moreno JA; Higueras C; Gonzalez-Mestre V; Clotet B
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):451-5. PubMed ID: 19320569
[TBL] [Abstract][Full Text] [Related]
19. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
[TBL] [Abstract][Full Text] [Related]
20. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study.
Mole B; Gillaizeau F; Carbonnel E; Pierre I; Brazille P; Grataloup C; Mercier S; Duracinsky M; Weiss L; Piketty C
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):251-8. PubMed ID: 21801082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
